HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Erythropoiesis-stimulating agents are effective in myelodysplastic syndromes, but are they safe?

AuthorsDavid P Steensma
JournalAmerican journal of hematology (Am J Hematol) Vol. 84 Issue 1 Pg. 3-5 (Jan 2009) ISSN: 1096-8652 [Electronic] United States
PMID19037863 (Publication Type: Comment, Editorial)
Chemical References
  • Hematinics
  • Recombinant Proteins
  • Erythropoietin
  • Darbepoetin alfa
Topics
  • Aged
  • Clinical Trials as Topic
  • Darbepoetin alfa
  • Erythropoietin (adverse effects, analogs & derivatives, economics)
  • Hematinics (adverse effects, economics)
  • Humans
  • Medicare Part D (economics, legislation & jurisprudence)
  • Myelodysplastic Syndromes (drug therapy)
  • Recombinant Proteins
  • United States

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: